BPC-157 is unregulated — but calling it 'untested' isn't quite right

What did @shredwithcaden actually say?

The creator warned viewers away from BPC-157 and TB-500, calling the evidence base thin and raising a specific cancer concern: because BPC-157 promotes angiogenesis, it could theoretically accelerate tumor growth in someone who has an undetected cancer. They also argued that influencers pushing peptide codes are financially conflicted, not medically informed, and that the absence of long-term human data makes the risk-benefit math impossible to solve.

To their credit, they did not sell anything. They were direct about their reasoning, and they named the specific mechanism they were worried about rather than just vaguely gesturing at danger. That is more intellectual honesty than most peptide content on this platform.

Does the science back this up?

Partially. The angiogenesis concern is real but stated in a way that overstates certainty. The evidence gap is real and understated.

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. The preclinical literature is actually substantial. Animal studies, largely in rats, have repeatedly shown accelerated tendon-to-bone healing, reduced inflammation, and gastroprotective effects. Sikiric et al. have published extensively on this, including work in Current Pharmaceutical Design (2018) documenting gastrointestinal and systemic effects in rodent models. Gwyer et al. (2019, Regenerative Medicine) reviewed the wound-healing literature and found consistent preclinical signals.

The angiogenesis-cancer concern has a theoretical basis. Tumor angiogenesis is a well-established mechanism in oncology, and VEGF-driven blood vessel formation is a target for approved cancer drugs. Whether BPC-157 acts through VEGF pathways specifically, and whether that would meaningfully accelerate a pre-existing tumor in a human, is not established in the literature. The creator presented a plausible hypothesis as a confirmed mechanism. Those are different things.

What did they get wrong (or right)?

They got the regulatory picture right. BPC-157 has no FDA-approved indication. It is not in any phase 3 human clinical trial. In 2022, the FDA prohibited its use in compounded preparations citing insufficient evidence of safety. That is a significant regulatory flag that most peptide promoters quietly ignore.

They got the angiogenesis framing partially wrong. Saying a brain tumor will "double in size at the normal rate" because of BPC-157 is a specific mechanistic claim without a study behind it. The concern is worth raising. The certainty is not warranted.

They also misidentified the peptide repeatedly, calling it "VPC 157" throughout, which matters less as a factual error and more as a signal that the creator is working from secondhand information rather than primary sources.

The financial conflict argument about influencers is accurate and worth saying out loud. Affiliate codes are a real incentive structure that distorts health recommendations. Full credit there.

What should you actually know?

If you are considering BPC-157, here is what the evidence actually supports and does not support. Preclinical data in animals is genuinely promising for musculoskeletal healing and gut protection. No large-scale randomized controlled human trial has confirmed these effects in people. The FDA's 2022 position is not based on evidence of harm, it is based on insufficient evidence of safety, which is a different but still serious concern.

The angiogenesis and tumor risk is a legitimate theoretical concern that has not been studied in humans. That means it cannot be dismissed, and it cannot be confirmed. If you have a personal or family history of cancer, or any unresolved diagnostic question, this uncertainty matters more to you than to someone without that history.

Anyone using peptides outside of a supervised clinical setting is operating without a safety net. That does not mean everyone who uses them is harmed, but it does mean that if something goes wrong, there is no established protocol for what went wrong or how to fix it. Working with a licensed provider who can order baseline labs, monitor your response, and adjust accordingly is not a marketing pitch. It is basic risk management.